Exploring Newer Strategies for Treating Chronic Noninfectious Uveitis

This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will examine the evidence for biologic immunomodulatory agents and intravitreal treatments in patients with chronic noninfectious uveitis. It will review their mechanism of action and key questions regarding their use, such as when to initiate these treatments, considerations when selecting between or combining treatments, how to monitor patients, and when to stop treatment.

‍

Upon completion of the educational activity, participants should be able to:

• Describe evidence-based approaches to treatment selection and the ongoing interprofessional management of noninfectious uveitis
• Evaluate pediatric patients with juvenile idiopathic arthritis-associated uveitis for disease severity, biopsychosocial burdens, comorbidities, and treatment responses
• Describe immunosuppressant therapy options for adults with autoimmune uveitis

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com